CAR-T Cell Therapy
What is CAR-T Cell Therapy?
CAR-T cell therapy, or Chimeric Antigen Receptor T-cell therapy, is an innovative form of immunotherapy used primarily to treat certain types of cancers, particularly hematological malignancies such as leukemia and lymphoma. In this treatment, a patient's own T cells — a type of immune cell — are collected, genetically modified in a laboratory to express special receptors (CARs) that recognize and attack cancer cells, and then infused back into the patient's body. CAR-T cells can persist in the body, providing ongoing surveillance against cancer cells, which can help prevent relapse.
Indications
CAR-T cell therapy is indicated for the following conditions:
- Relapsed or refractory B-cell acute lymphoblastic leukemia (ALL)
- Diffuse large B-cell lymphoma (DLBCL)
- Multiple myeloma not responding to conventional therapy
- Follicular lymphoma (relapsed/refractory)
- Mantle cell lymphoma
Who needs CAR-T Cell Therapy?
CAR-T cell therapy is typically considered for patients with blood cancers that have relapsed or not responded to standard treatments:
- Relapsed leukemia: Leukemia that has returned after previous treatment.
- Refractory lymphoma: Lymphoma that has not responded to at least two prior lines of therapy.
- Multiple myeloma: Cancer of plasma cells in the bone marrow.
- ALL in children and young adults: Acute lymphoblastic leukemia unresponsive to standard chemotherapy.
Other conditions that may require CAR-T Cell Therapy include: Primary mediastinal B-cell lymphoma, High-grade B-cell lymphoma, Transformed follicular lymphoma, Certain solid tumors (under clinical trial investigation).
CAR-T therapy can come with significant side effects including cytokine release syndrome (CRS) and neurotoxicity, requiring careful management by specialized teams.
T-cell collection
CAR-T therapy uses the patient's own T cells (autologous). T cells are collected from the patient's blood through a process called leukapheresis, then sent to a specialized laboratory for genetic modification.
Eligibility requirements
- Confirmed diagnosis of a CAR-T-eligible cancer type
- Failure of at least two prior lines of therapy (in most indications)
- Adequate organ function (heart, kidneys, liver)
- No active uncontrolled infections
- Performance status adequate to tolerate the therapy
- No active autoimmune disease requiring immunosuppression
Evaluation process
Patients undergo comprehensive evaluation including bone marrow biopsy, PET/CT imaging, blood tests, and organ function assessments. The oncology team determines eligibility and designs the treatment protocol before T-cell collection begins.
What are our services?
We are offering the following specialized services to all patients at renowned hospitals in India and Türkiye. Our organization is proudly partnered with multiple accredited hospitals across both countries, known for their strong reputations, state-of-the-art infrastructure, and patient-centric approach.
These hospitals provide a world-class healthcare environment with excellent ambience, comprehensive diagnostic and treatment facilities, and strict infection control protocols. Each center is equipped with advanced medical technology and a highly skilled multidisciplinary team capable of managing even the most complex cases. With a strong track record of successful outcomes, these hospitals ensure quality care at every step of the patient journey — from pre-treatment evaluation and surgery to post-operative care and long-term follow-up.